CN111638332B - Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit - Google Patents
Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit Download PDFInfo
- Publication number
- CN111638332B CN111638332B CN202010669794.6A CN202010669794A CN111638332B CN 111638332 B CN111638332 B CN 111638332B CN 202010669794 A CN202010669794 A CN 202010669794A CN 111638332 B CN111638332 B CN 111638332B
- Authority
- CN
- China
- Prior art keywords
- nta
- novel coronavirus
- solution
- protein
- igm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 35
- 238000001514 detection method Methods 0.000 title claims abstract description 31
- 238000002965 ELISA Methods 0.000 title claims abstract description 28
- 239000003085 diluting agent Substances 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 239000013642 negative control Substances 0.000 claims abstract description 17
- 239000013641 positive control Substances 0.000 claims abstract description 15
- 238000005406 washing Methods 0.000 claims abstract description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 13
- 239000012089 stop solution Substances 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 101710139375 Corneodesmosin Proteins 0.000 claims description 19
- 101710141454 Nucleoprotein Proteins 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 8
- 229940098773 bovine serum albumin Drugs 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 102100031673 Corneodesmosin Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 20
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 238000011330 nucleic acid test Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a novel coronavirus IgA/IgM/IgG antibody ELISA detection kit, which belongs to the technical field of biological detection, and comprises an ELISA plate, substrate liquid, sample diluent, positive control liquid, negative control liquid, concentrated washing liquid, enzyme conjugate and stop solution, wherein the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein, the enzyme conjugate is mouse anti-human IgA/IgM/IgG-HRP antibody diluent marked by horseradish peroxidase, and the detection is carried out through immune specificity reaction of antigen antibody so as to qualitatively judge whether novel coronavirus antibody exists in a test sample, and the kit has high sensitivity and high specificity; the kit detects through the immunospecific reaction of the antigen and the antibody, has the characteristics of high specificity and high accuracy, is simple and convenient in step, reasonable in design and suitable for popularization.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a novel coronavirus IgA/IgM/IgG antibody ELISA detection kit.
Background
Common signs of novel coronaviruses (2019-nCoV) are fever, hypodynamia, dry cough and dyspnea gradually, and partial patients have slight symptoms and even have clinical symptom-free patients, and the novel coronaviruses have the characteristics of people, the common incubation period is 1-14 days, the incubation period is infectious, asymptomatic infectious people can become an infectious source, and the novel coronaviruses are mainly transmitted through respiratory tract droplets and close contact infection, so that the population is generally susceptible.
Currently, 2019-nCoV nucleic acid detection is a routine detection method and diagnostic basis for diagnosing COVID-19. However, the detection of nucleic acids has a false negative problem due to the influence of various factors such as sample collection and storage, virus-infected sites, RNA extraction methods, and quality problems of nucleic acid detection kits. With the research and development of 2019-nCoV IgM and IgG antibody immunodetection kit, the antibody detection can effectively make up the risk of missed detection of nucleic acid detection, and plays a significant role in diagnosis, treatment, prevention and control of COVID-19 in time.
At present, a method and a corresponding kit for detecting 2019-nCoV IgM/IgG antibodies have certain researches and reports, and certain products are marketed. The existing methods for detecting 2019-nCoV antibodies comprise a common ELISA method, a fluorescence immunoassay method, a radioimmunoassay method, a chemiluminescence method and the like, and have certain defects. The common ELISA kit uses prokaryotic expression recombinant protein or cultured whole virus as a coating antigen, but has lower sensitivity and specificity. Therefore, due to the special properties of 2019-nCov-SARS, development of a novel coronavirus ELISA detection kit with good specificity and high sensitivity is needed.
Disclosure of Invention
The invention aims to provide a novel coronavirus IgA/IgM/IgG antibody ELISA detection kit, which solves the problems in the prior art, adopts His+N protein gene+glycine flexible peptide+S protein gene to be inserted into PET-28a carrier to construct prokaryotic expression carrier to obtain recombinant protein, coats a microplate and forms a kit of 2019-nCoV IgA/IgM/IgG antibody, besides the advantages of the common ELISA detection kit, the kit also overcomes the defect of low sensitivity caused by recombinant antigen, and improves the detection sensitivity and specificity.
In order to achieve the above object, the present invention provides the following solutions:
the invention provides a novel coronavirus IgA/IgM/IgG antibody ELISA detection kit, which comprises an ELISA plate, substrate liquid, sample diluent, positive control liquid, negative control liquid, concentrated washing liquid, enzyme conjugate and stop solution, wherein the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein;
the enzyme conjugate is a murine anti-human IgA/IgM/IgG working solution prepared by enzyme-labeled diluent according to working concentration.
Further, the enzyme conjugate is a horseradish peroxidase-labeled murine anti-human IgA/IgM/IgG-HRP antibody dilution.
Further, the novel coronavirus is coated after being blocked by bovine serum albumin with the mass concentration of 1-10%.
Further, the novel coronavirus was coated in an amount of 0.1. Mu.g/well.
Further, the sample diluent is phosphate buffer solution with pH of 7.2-7.4 containing 1-10% of bovine serum albumin by mass fraction.
Further, the concentrated washing solution is phosphate buffer solution with pH of 7.2-7.4 and containing 0.05% Tween-20 by volume fraction, and the stopping solution is sulfuric acid solution with concentration of 2 mol/L.
Further, the positive control solution is prepared by adding positive serum into a sample diluent according to the proportion of 1:30-1:100, and the absorbance value of the positive control solution is greater than 1.0;
the negative control serum is prepared by adding negative serum into a sample diluent according to the proportion of 5wt%, and the absorbance value of the negative control serum is less than 0.1.
Further, the preparation method of the novel coronavirus S+N recombinant protein comprises the following steps:
(1) According to the N and S protein gene sequences of SARS-COV-2 reported in GenBank, specific primers are designed for the amplification of the N and S protein genes respectively; inserting an N protein gene, glycine flexible peptide, an S protein gene and a His gene into a PET-28a vector through target fragment amplification, enzyme digestion, connection and transformation to obtain a plasmid containing N and S protein gene sequences, wherein the sequences are shown as SEQ ID No.1, the full length of the N protein gene is 1257bp, 419 amino acids are encoded, the full length of the S protein gene is 1479bp, and 493 amino acids are encoded;
(2) Carrying out protein expression on plasmids containing N and S protein gene sequences by using escherichia coli, carrying out ultrasound on thalli, dissolving sediment by using 50mM Tris+2M urea pH=12 overnight, centrifuging, and dialyzing supernatant to a Tris solution with pH=9.5 to obtain protein;
the dialysis procedure was as follows: loading NTA resin into a chromatographic column, adding target protein into the NTA chromatographic column, washing with 10 times of NTA volume of NTA-0Buffer at a flow rate of 15mL/h, collecting the penetrating part, eluting with 5 times of NTA volumes of NTA-20, NTA-40, NTA-60, NTA-100 and NTA-500 respectively at a flow rate of 15mL/h, and collecting the eluent;
(3) SDS/PAGE analysis is carried out to determine the distribution of target proteins in the eluent, and the target proteins are collected.
The invention discloses the following technical effects:
the novel coronavirus IgA/IgM/IgG antibody ELISA detection kit disclosed by the invention adopts His+N protein gene+glycine flexible peptide+S protein gene to be inserted into a PET-28a carrier to construct a prokaryotic expression carrier to obtain recombinant protein, and the prokaryotic expression carrier is coated with a micropore plate to form a 2019-nCoV IgA/IgM/IgG antibody kit.
The kit comprises an ELISA plate, substrate liquid, sample diluent, positive control liquid, negative control liquid, concentrated washing liquid, enzyme conjugate and stop solution, wherein the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein, the enzyme conjugate is mouse anti-human IgA/IgM/IgG-HRP antibody diluent marked by horseradish peroxidase, and the detection is carried out through the immunospecific reaction of antigen antibody so as to qualitatively judge whether the novel coronavirus antibody exists in a test sample, thereby having high sensitivity and high specificity.
The novel coronavirus IgA/IgM/IgG antibody ELISA detection kit detects through the immunospecific reaction of antigen and antibody, has the characteristics of high specificity and high accuracy, is simple and convenient in step, reasonable in design and suitable for popularization.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is an SDS/PAGE electrophoresis of the recombinant protein of example 1.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
Example 1
The preparation method of the novel coronavirus S+N recombinant protein comprises the following steps:
(1) According to the N and S protein gene sequences of SARS-COV-2 reported in GenBank, specific primers are designed for the amplification of the N and S protein genes respectively; inserting an N protein gene, glycine flexible peptide, an S protein gene and a His gene into a PET-28a vector through target fragment amplification, enzyme digestion, connection and transformation to obtain a plasmid containing N and S protein gene sequences, wherein the sequences are shown as SEQ ID No.1, the full length of the N protein gene is 1257bp, 419 amino acids are encoded, the full length of the S protein gene is 1479bp, and 493 amino acids are encoded;
(2) Carrying out protein expression on plasmids containing N and S protein gene sequences by using escherichia coli, carrying out ultrasound on thalli, dissolving sediment by using 50mM Tris+2M urea pH=12 overnight, centrifuging, and dialyzing supernatant to a Tris solution with pH=9.5 to obtain protein;
the dialysis procedure was as follows: loading NTA resin into a chromatographic column, adding target protein into the NTA chromatographic column, washing with 10 times of NTA volume of NTA-0Buffer at a flow rate of 15mL/h, collecting the penetrating part, eluting with 5 times of NTA volumes of NTA-20, NTA-40, NTA-60, NTA-100 and NTA-500 respectively at a flow rate of 15mL/h, and collecting the eluent;
(3) SDS/PAGE analysis was performed to determine the distribution of the target protein in the eluate, as shown in FIG. 1, and the target protein was collected.
NAT buffer:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;
NAT buffer-20:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;20mmol/L Imidazole;
NAT buffer-40:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;40mmol/L Imidazole;
NAT buffer-60:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;60mmol/L Imidazole;
NAT buffer-100:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;100mmol/L Imidazole;
NAT buffer-500:20mmol/L Tris-Hcl,PH7.9,0.5mol/L NaCl,10%Glyerol;500mmol/L Imidazole。
Example 2
A novel coronavirus IgA/IgM/IgG antibody ELISA detection kit comprises an ELISA plate, substrate liquid, sample diluent, positive control liquid, negative control liquid, concentrated washing liquid, enzyme conjugate and stop solution, wherein the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein.
In this example, the enzyme conjugate is a horseradish peroxidase-labeled murine anti-human IgA/IgM/IgG-HRP antibody dilution.
In this example, the novel coronavirus was encapsulated with bovine serum albumin at a mass concentration of 5%.
In this example, the novel coronavirus was coated in an amount of 0.1. Mu.g/well.
In this example, the sample diluent is phosphate buffer at pH7.2-7.4 containing 5% by mass of bovine serum albumin.
In this example, the concentrated washing solution was phosphate buffer of pH7.2-7.4 containing 0.05% Tween-20 by volume fraction, and the stop solution was 2mol/L sulfuric acid solution.
In this example, the substrate solution contained 0.06wt% TMB hydrochloride in citric acid buffer, 0.001wt% sodium thiosulfate and 0.02wt% sodium carbonate.
In this embodiment, the positive control solution is prepared by adding positive serum into a sample diluent according to a ratio of 1:70, and the absorbance value of the positive control solution is greater than 1.0;
the negative control serum is prepared by adding negative serum into a sample diluent according to the proportion of 5wt%, and the absorbance value of the negative control serum is less than 0.1.
Example 3
A novel coronavirus IgA/IgM/IgG antibody ELISA detection kit comprises an ELISA plate, substrate liquid, sample diluent, positive control liquid, negative control liquid, concentrated washing liquid, enzyme conjugate and stop solution, wherein the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein.
In this example, the enzyme conjugate is a horseradish peroxidase-labeled murine anti-human IgA/IgM/IgG-HRP antibody dilution.
In this example, the novel coronavirus was encapsulated with bovine serum albumin at a mass concentration of 1%.
In this example, the novel coronavirus was coated in an amount of 0.1. Mu.g/well.
In this example, the sample diluent is phosphate buffer at pH7.2-7.4 containing 10% by mass of bovine serum albumin.
In this example, the concentrated washing solution was phosphate buffer of pH7.2-7.4 containing 0.05% Tween-20 by volume fraction, and the stop solution was 2mol/L sulfuric acid solution.
In the embodiment, the positive control solution is prepared by adding positive serum into a sample diluent according to the ratio of 1:30, and the absorbance value of the positive control solution is greater than 1.0;
the negative control serum is prepared by adding negative serum into a sample diluent according to the proportion of 5wt%, and the absorbance value of the negative control serum is less than 0.1.
Test example 1 detection test was performed using the kit of example 1
1. Reagent and sample preparation:
the reagent is rewarmed before use;
dilution of concentrated washing solution: 25mL of the concentrated washing solution is taken, 475mL of purified water is added for dilution, and shaking and mixing are carried out.
Enzyme conjugate dilution: 1mL of the sample dilution was taken, 10. Mu.L of the enzyme conjugate was added, and mixed by shaking.
Sample to be measured: the sample to be tested is subjected to 100-fold pre-dilution. And taking 2 mu L of a sample to be tested, adding 198 mu L of sample diluent, and shaking and uniformly mixing.
2. Detection method
The desired ELISA plate was removed, allowed to return to room temperature, 300. Mu.L of diluted wash solution was added to each well, and allowed to stand for 30s. Negative control 3 wells and positive control 2 wells were added, 100 μl per well. The diluted sample to be tested was added at 100. Mu.L per well.
And (3) sealing the plates by using sealing plates, and incubating for 30min at 37 ℃. The liquid was discarded, 300 μl of wash solution (1×) was added to each well using an automatic plate washer, repeated 5 times, and finally patted dry on a clean paper towel. All wells were added with 100. Mu.L of diluted murine anti-human IgA/IgM/IgG-HRP antibody. And (3) sealing the plates by using sealing plates, and incubating for 30min at 37 ℃. After 3 washes, 100. Mu.L of substrate solution was added to each well and incubated at 37℃for 10min. 100. Mu.L of stop solution was added to each well. In half an hour, dual wavelength detection is performed on an enzyme-labeled instrument, OD450 is read, and OD570 or OD630 is used as a reference wavelength. OD450-OD570 (or OD 630) is the calibration value.
3. Interpretation of
The average OD of the negative control was 2.1 times as high as the Cutoff value, e.g., the average OD of the negative control was less than 0.05 calculated as 0.05. A value greater than or equal to Cutoff may be judged positive, and a value less than Cutoff may be judged negative.
Test example 2 determination of the coating concentrations of antigen at different concentrations
1. Coating
Homemade s+n protein: 1350. Mu.l PBS+4. Mu.l to 5. Mu.g/ml; 400 μl+600 μl PBS was used to make 2 μg/ml;50 μl/well. Coating overnight at 4 ℃.
2.Blocking
Mu.l Blocking was added to each well and incubated with shaking at room temperature for 2h.
3. First antibody
IgA/IgM/IgG antibodies were: anti-N protein and anti-S protein: 225. Mu.l of AB+12.5. Mu.l of anti-N protein+12.5. Mu.l of anti-S protein were prepared 10X, 25. Mu.l+225. Mu.l of AB were prepared 100X, 25. Mu.l+225. Mu.l of AB were prepared 1000X, 100. Mu.l/well. Negtive was added to 100 μ lAB.
4. Secondary antibody (HRP mouse anti-human IgA/IgM/IgG)
850. Mu.l+0.34. Mu.l anti-human IgA+0.34. Mu.l anti-human IgM+0.34. Mu.l anti-human IgG.
The results of the detection are shown in Table 1.
TABLE 1 comparison of the coating amounts of different antigens
Test example 3 Performance test
182 clinical serum samples are detected together, wherein 134 negative samples are detected, the detection result is 130 negative samples, and the coincidence rate is 97% (130/134); the total number of positive samples is 48, wherein 35 positive samples of the diagnosed patient and 13 positive samples of the recovered patient are detected to be 46 minutes positive, and the coincidence rate is 95.8 percent (46/48), so that the product has strong precision and good stability.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Sequence listing
<110> Zhejiang province people Hospital
<120> novel coronavirus IgA/IgM/IgG antibody ELISA detection kit
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2826
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 1
atgagcgata acggtccgca aaaccagcgt aacgcgccgc gtattacctt cggtggtccg 60
agcgatagca ccggtagcaa ccaaaacggc gaacgtagcg gtgcgcgtag caaacaacgt 120
cgtccgcaag gtctgccgaa caacaccgcg agctggttta ccgcgctgac ccagcacggt 180
aaagaagacc tgaagttccc gcgtggtcag ggcgtgccga ttaacaccaa cagcagcccg 240
gacgatcaaa ttggttatta ccgtcgtgcg acccgtcgta tccgtggcgg tgatggcaaa 300
atgaaagatc tgagcccgcg ttggtacttc tattacctgg gtaccggccc ggaagcgggt 360
ctgccgtacg gtgcgaacaa ggatggcatc atctgggttg cgaccgaagg tgcgctgaac 420
accccgaaag accacattgg tacccgtaac ccggcgaaca acgcggcgat tgttctgcag 480
ctgccgcaag gtaccaccct gccgaaaggt ttctatgcgg agggtagccg tggtggtagc 540
caagcgagca gccgtagcag cagccgtagc cgtaacagca gccgtaacag caccccgggt 600
agcagccgtg gtaccagccc ggcgcgtatg gcgggtaacg gtggcgatgc ggcgctggcg 660
ctgctgctgc tggatcgtct gaaccaactg gagagcaaga tgagcggcaa gggtcagcaa 720
caacagggtc aaaccgttac caaaaagagc gcggcggaag cgagcaagaa accgcgtcag 780
aaacgtaccg cgaccaaggc gtacaacgtg acccaggcgt ttggtcgtcg tggtccggaa 840
caaacccagg gcaactttgg tgaccaagaa ctgatccgtc aaggcaccga ctacaaacac 900
tggccgcaga tcgcgcaatt cgcgccgagc gcgagcgcgt tctttggtat gagccgtatt 960
ggtatggaag tgaccccgag cggtacctgg ctgacctaca ccggtgcgat caaactggac 1020
gataaggacc cgaacttcaa agaccaagtg atcctgctga acaagcacat cgacgcgtac 1080
aaaacctttc cgccgaccga gccgaagaaa gacaagaaga aaaaggcgga tgaaacccag 1140
gcgctgccgc aacgtcagaa aaagcaacag accgtgaccc tgctgccggc ggcggatctg 1200
gacgatttca gcaaacagct gcagcaaagc atgagcagcg cggatagcac ccaagcgggc 1260
ggtggcggct ctggcggcgg tggttctggc ggcggtggct ccatgttcgt tttcctggtt 1320
ctgctgccgc tggttagcag ccaatgcgtg aatctgacca cccgcaccca actgccgccg 1380
gcgtacacca acagcttcac ccgtggtgtt tactatccgg acaaagtttt tcgtagcagc 1440
gtgctgcaca gcacccagga cctgttcctg ccgttcttta gcaacgttac ctggttccac 1500
gcgatccacg tgagcggcac caacggcacc aagcgtttcg acaacccggt gctgccgttt 1560
aacgatggtg tttacttcgc gagcaccgag aagagcaaca tcattcgtgg ttggattttt 1620
ggcaccaccc tggacagcaa aacccagagc ctgctgatcg ttaacaacgc gaccaacgtg 1680
gttattaagg tgtgcgagtt ccaattttgc aacgatccgt tcctgggcgt ttactatcac 1740
aagaacaaca aaagctggat ggagagcgaa tttcgtgttt atagcagcgc gaacaactgc 1800
acctttgagt acgtgagcca gccgttcctg atggacctgg aaggcaagca aggcaacttc 1860
aaaaacctgc gtgagttcgt gttcaagaac attgatggtt acttcaaaat ctacagcaag 1920
cacaccccga tcaacctggt tcgtgacctg ccgcagggtt ttagcgcgct ggagccgctg 1980
gttgacctgc cgatcggtat taacatcacc cgttttcaaa ccctgctggc gctgcaccgt 2040
agctacctga cgccgggtga cagcagcagc ggttggaccg ctggtgctgc ggcgtactat 2100
gttggttacc tgcaaccgcg taccttcctg ctgaaataca acgaaaacgg caccatcacc 2160
gatgcggttg attgcgcgct ggacccgctg agcgaaacca agtgcaccct gaagagcttc 2220
accgtggaga agggtattta tcagaccagc aacttccgtg tgcaaccgac cgaaagcatt 2280
gttcgttttc cgaacatcac caacctgtgc ccgtttggcg aggttttcaa cgcgacccgt 2340
ttcgcgagcg tgtatgcgtg gaaccgtaaa cgtatcagca actgcgttgc ggactatagc 2400
gtgctgtaca acagcgcgag cttcagcacc tttaagtgct atggtgtgag cccgaccaaa 2460
ctgaacgatc tgtgctttac caacgtttac gcggatagct tcgtgattcg tggcgacgag 2520
gttcgtcaga tcgcgccggg tcaaaccggc aagattgcgg actacaacta taaactgccg 2580
gacgatttca ccggctgcgt tatcgcgtgg aacagcaaca acctggatag caaagtgggt 2640
ggcaactaca actatctgta ccgtctgttt cgtaagagca acctgaaacc gttcgagcgt 2700
gacattagca ccgaaatcta ccaggcgggt agcaccccgt gcaacggtgt tgagggcttt 2760
aactgctatt tcccgctgca aagctacggt ttccaaccga ccaacggtgt tggttaccag 2820
ccgtac 2826
Claims (1)
1. The novel coronavirus IgA/IgM/IgG antibody ELISA detection kit comprises an ELISA plate, a substrate solution, a sample diluent, a positive control solution, a negative control solution, a concentrated washing solution, an enzyme conjugate and a stop solution, and is characterized in that the ELISA plate is pre-coated with novel coronavirus S+N recombinant protein;
the enzyme conjugate is horseradish peroxidase marked mouse anti-human IgA/IgM/IgG-HRP antibody diluent; the novel coronavirus is coated after being sealed by bovine serum albumin with the mass concentration of 1-10%; the coating amount of the novel coronavirus is 0.1 mug/well; the sample diluent is phosphate buffer solution with the pH value of 7.2-7.4 and containing 1-10% of bovine serum albumin by mass fraction; the concentrated washing liquid is phosphate buffer solution with the pH value of 7.2-7.4 and containing 0.05% Tween-20 by volume fraction, and the stop solution is sulfuric acid solution with the concentration of 2 mol/L; the positive control solution is prepared by adding positive serum into a sample diluent according to the proportion of 1:30-1:100, and the absorbance value of the positive control solution is greater than 1.0; the negative control serum is prepared by adding negative serum into a sample diluent according to the proportion of 5wt%, and the absorbance value of the negative control serum is less than 0.1;
the preparation method of the novel coronavirus S+N recombinant protein comprises the following steps:
(1) Designing specific primers for amplifying two genes of N and S proteins respectively; inserting an N protein gene, glycine flexible peptide, S protein gene and His gene into a PET-28a vector through target fragment amplification, enzyme digestion, connection and transformation to obtain a plasmid containing N and S protein gene sequences, wherein the sequences are shown as SEQ ID No.1, the full length of the N protein gene is 1257bp, 419 amino acids are encoded, the full length of the S protein gene is 1479bp, and 493 amino acids are encoded;
(2) Carrying out protein expression on plasmids containing N and S protein gene sequences by using escherichia coli, carrying out ultrasound on thalli, dissolving sediment by using 50mM Tris+2M urea pH=12 overnight, centrifuging, and dialyzing supernatant to a Tris solution with pH=9.5 to obtain protein;
the dialysis procedure was as follows: loading NTA resin into a chromatographic column, adding target protein into the NTA chromatographic column, washing with 10 times of NTA volume of NTA-0Buffer at a flow rate of 15mL/h, collecting the penetrating part, eluting with 5 times of NTA volumes of NTA-20, NTA-40, NTA-60, NTA-100 and NTA-500 respectively at a flow rate of 15mL/h, and collecting the eluent;
(3) SDS/PAGE analysis is carried out to determine the distribution of target proteins in the eluent, and the target proteins are collected.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010669794.6A CN111638332B (en) | 2020-07-13 | 2020-07-13 | Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010669794.6A CN111638332B (en) | 2020-07-13 | 2020-07-13 | Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111638332A CN111638332A (en) | 2020-09-08 |
CN111638332B true CN111638332B (en) | 2023-12-19 |
Family
ID=72328710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010669794.6A Active CN111638332B (en) | 2020-07-13 | 2020-07-13 | Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111638332B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112114141A (en) * | 2020-09-11 | 2020-12-22 | 博奥赛斯(天津)生物科技有限公司 | Novel coronavirus IgA antibody chemiluminescence detection kit |
CN112114139A (en) * | 2020-09-11 | 2020-12-22 | 博奥赛斯(天津)生物科技有限公司 | Novel coronavirus IgM-IgA-IgG antibody colloidal gold detection kit |
CN112666348A (en) * | 2020-10-27 | 2021-04-16 | 山西高等创新研究院 | Detection proteome of novel coronavirus SARS-CoV-2 and application thereof |
CN114441751A (en) * | 2020-11-02 | 2022-05-06 | 郑州达诺生物技术有限公司 | New coronavirus total antibody enzyme-linked immunoassay kit |
CN112630426B (en) * | 2020-11-17 | 2023-12-22 | 上海优晶生物科技有限公司 | Colloidal gold test strip for detecting novel coronavirus COVID-19 |
CN112881681A (en) * | 2020-12-09 | 2021-06-01 | 安徽医科大学 | Indirect ELISA detection method for SARS-CoV-2N protein IgA |
CN112698030B (en) * | 2020-12-10 | 2022-02-01 | 丹娜(天津)生物科技股份有限公司 | Kit for detecting novel coronavirus antibody based on enzyme-linked immunosorbent assay |
CN113917138A (en) * | 2021-09-03 | 2022-01-11 | 北京科兴中维生物技术有限公司 | Novel coronavirus IgG antibody level detection kit |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469126A (en) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | Method for detecting SARS coronavirus antibody and its reagent kit |
CN206649044U (en) * | 2016-12-07 | 2017-11-17 | 天津纳涵科技有限公司 | A kind of detection test card that can detect IgG, IgM and IgA simultaneously |
CN111122879A (en) * | 2020-03-26 | 2020-05-08 | 珠海丽珠试剂股份有限公司 | Coating liquid of novel coronavirus recombinant antigen, pretreatment method, application and product |
CN111122864A (en) * | 2020-03-25 | 2020-05-08 | 中山生物工程有限公司 | Novel coronavirus IgG antibody enzyme-linked immunoassay kit and detection method thereof |
CN111208298A (en) * | 2020-02-11 | 2020-05-29 | 潍坊市康华生物技术有限公司 | 2019 novel coronavirus antibody detection kit and preparation method thereof |
CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
CN111239392A (en) * | 2020-02-26 | 2020-06-05 | 浙江诺迦生物科技有限公司 | Novel coronavirus pneumonia (COVID-19) serological diagnosis kit |
CN111239394A (en) * | 2020-03-09 | 2020-06-05 | 四川省人民医院 | Novel coronavirus antibody rapid detection kit based on mixed antigens |
CN111289745A (en) * | 2020-03-25 | 2020-06-16 | 中山生物工程有限公司 | Novel coronavirus IgM antibody enzyme-linked immunoassay kit and detection method thereof |
CN111303297A (en) * | 2020-02-14 | 2020-06-19 | 中国人民解放军总医院 | Recombinant protein for detecting 2019 novel coronavirus antibody by double-antigen sandwich method, test strip, preparation method and application |
CN111337689A (en) * | 2020-04-03 | 2020-06-26 | 山西医科大学 | Novel coronavirus detection kit |
CN111366734A (en) * | 2020-03-20 | 2020-07-03 | 广州市康润生物科技有限公司 | Method for screening new coronavirus through double indexes and predicting severe pneumonia |
CN111378789A (en) * | 2020-06-01 | 2020-07-07 | 广州凯普医药科技有限公司 | Respiratory tract infection pathogen nucleic acid joint detection kit |
CN111398581A (en) * | 2020-02-27 | 2020-07-10 | 四川省人民医院 | COVID-19 rapid diagnosis kit and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201616590D0 (en) * | 2016-09-29 | 2016-11-16 | Oxford Nanopore Technologies Limited | Method |
-
2020
- 2020-07-13 CN CN202010669794.6A patent/CN111638332B/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469126A (en) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | Method for detecting SARS coronavirus antibody and its reagent kit |
CN206649044U (en) * | 2016-12-07 | 2017-11-17 | 天津纳涵科技有限公司 | A kind of detection test card that can detect IgG, IgM and IgA simultaneously |
CN111208298A (en) * | 2020-02-11 | 2020-05-29 | 潍坊市康华生物技术有限公司 | 2019 novel coronavirus antibody detection kit and preparation method thereof |
CN111303297A (en) * | 2020-02-14 | 2020-06-19 | 中国人民解放军总医院 | Recombinant protein for detecting 2019 novel coronavirus antibody by double-antigen sandwich method, test strip, preparation method and application |
CN111239392A (en) * | 2020-02-26 | 2020-06-05 | 浙江诺迦生物科技有限公司 | Novel coronavirus pneumonia (COVID-19) serological diagnosis kit |
CN111398581A (en) * | 2020-02-27 | 2020-07-10 | 四川省人民医院 | COVID-19 rapid diagnosis kit and preparation method thereof |
CN111239394A (en) * | 2020-03-09 | 2020-06-05 | 四川省人民医院 | Novel coronavirus antibody rapid detection kit based on mixed antigens |
CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
CN111366734A (en) * | 2020-03-20 | 2020-07-03 | 广州市康润生物科技有限公司 | Method for screening new coronavirus through double indexes and predicting severe pneumonia |
CN111122864A (en) * | 2020-03-25 | 2020-05-08 | 中山生物工程有限公司 | Novel coronavirus IgG antibody enzyme-linked immunoassay kit and detection method thereof |
CN111289745A (en) * | 2020-03-25 | 2020-06-16 | 中山生物工程有限公司 | Novel coronavirus IgM antibody enzyme-linked immunoassay kit and detection method thereof |
CN111122879A (en) * | 2020-03-26 | 2020-05-08 | 珠海丽珠试剂股份有限公司 | Coating liquid of novel coronavirus recombinant antigen, pretreatment method, application and product |
CN111337689A (en) * | 2020-04-03 | 2020-06-26 | 山西医科大学 | Novel coronavirus detection kit |
CN111378789A (en) * | 2020-06-01 | 2020-07-07 | 广州凯普医药科技有限公司 | Respiratory tract infection pathogen nucleic acid joint detection kit |
Also Published As
Publication number | Publication date |
---|---|
CN111638332A (en) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111638332B (en) | Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit | |
US20230296601A1 (en) | Novel coronavirus antibody detection kit based on magnetic particle chemiluminescence | |
US20230220052A1 (en) | Iga antibody specifically recognizing rbd protein and testing kit | |
EP2064551B1 (en) | Combination hepatitis c virus antigen and antibody detection method | |
CN111505286A (en) | Novel coronavirus specific antibody double-antigen sandwich E L ISA detection kit and preparation method thereof | |
WO2010064435A1 (en) | Method for measuring cystatin c in human body fluid | |
JP5199067B2 (en) | Immunoagglutination reagent kit and antigen measurement method | |
CN104764888A (en) | Anti-cyclic citrullinated peptide antibody detection reagent kit | |
CN111562365B (en) | Novel coronavirus IgG/IgA antibody detection kit | |
EP4113121A1 (en) | Antigen for 2019 novel coronavirus and detection use thereof | |
CN102221616B (en) | Indirect ELISA (Enzyme-Linked Immuno Sorbent Assay) diagnostic kit of mycoplasma gallisepticum | |
CN111796090B (en) | Time-resolved fluorescence immunochromatographic assay test strip for echinococcosis granulosus of cattle and preparation method thereof | |
CN107219365A (en) | A kind of chemiluminescence detection kit based on foot and mouth disease virus 3B neoepitope Westerns | |
CN105732810A (en) | Procalcitonin monoclonal antibody and application thereof | |
CN114295829A (en) | Novel coronavirus antigen and total antibody combined detection kit and detection method | |
WO2012100599A1 (en) | Use of peroxiredoxin iv in preparing in vitro diagnostic reagents for rheumatoid arthritis | |
CN204389505U (en) | A kind of enzyme linked immunological kit detecting giant panda western-style fumatory ham | |
CN113447657B (en) | Detection kit for detecting anti-aconitate hydratase-IgG antibody | |
CN114057860B (en) | Specific histidine methylation modified S100A9 protein immunogen, polyclonal antibody and preparation method thereof | |
CN115656518A (en) | Detection kit for determining heparin binding protein in human plasma and urine | |
CN113563479B (en) | Echinococcosis diagnostic kit | |
White et al. | Rapid diagnosis of Legionnaires' disease. | |
CN112444626B (en) | African swine fever virus antibody ELISA detection kit and preparation method thereof | |
CN118624897A (en) | EB virus NA1 recombinant antigen coated plate and EB virus NA1-IgA antibody enzyme-linked immunosorbent assay kit | |
CN118501470A (en) | Detection kit for Leme disease spirochete IgM antibody and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |